Dr. Reddy’s, Alvotech to co-develop, market biosimilar of Merck’s cancer drug Keytruda
The Hindu
Dr. Reddy's and Alvotech collaborate to develop biosimilar to Keytruda, enhancing oncology capabilities and global reach.
Pharma major Dr. Reddy’s Laboratories and Nasdaq-listed global biotech firm Alvotech will co-develop, manufacture and commercialise a biosimilar candidate to Merck’s cancer drug Keytruda (pembrolizumab) for global markets.
They will be jointly responsible for developing and manufacturing the biosimilar candidate and sharing costs as well as the responsibilities. “Subject to certain exceptions, each party will have the right to commercialise the product globally,” Dr. Reddy’s and Alvotech said on Thursday (June 5, 2025) in a joint statement announcing the signing of a licence agreement.
The collaboration will combine their proven capabilities in biosimilars thus speeding up the development process and extending global reach for the biosimilar candidate. A registered trademark of Merck Sharp & Dohme Corp, Keytruda is indicated for the treatment of numerous cancer types. In 2024, the worldwide sales of Keytruda were $29.5 billion.
“Oncology has been a top focus therapy area for us and this collaboration will further enhance our capabilities in oncology, as pembrolizumab currently represents one of the most critical therapies in immuno-oncology,” Dr. Reddy’s CEO Erez Israeli said.
Alvotech chairman and CEO Robert Wessman said “we are pleased to enter into this collaboration for pembrolizumab with Dr. Reddy’s. This agreement demonstrates Alvotech’s ability to leverage its dedicated R&D and manufacturing platform for biosimilars, accelerating the expansion of our pipeline by pursuing growing global markets.”
The GPU sector is dominated by Nvidia, now the world's most valuable company thanks to frenzied global demand and optimism for AI.
1.2L Turbocharged iTurbo Revotron engine and a twin-cylinder iCNG technology paired with an AMT gearbox.
The Passenger Vehicle PV) segment clocked its highest-ever sales in a calendar year 2025 (CY25) at 44.90 lakh units, growing 5% Year on Year (YoY) driven by Q3 offtake, according to the data released by the Society of Indian Automobile Manufacturers (SIAM) on Tuesday.
Human + AI will define the future of work and nearly all HR leaders (97%) anticipate that by 2027, the nature of work will be shaped by humans working alongside AI rather than engaging with it only intermittently, said a Nasscom study conducted in association with Indeed, a US-based job site.
Central bankers express unity with Fed Chair Powell, emphasizing the importance of central bank independence amid political pressures.
Rice exporters urge India's Commerce Ministry for assistance in clearing payments amid Iran's civil unrest impacting trade.
PFRDA forms an expert committee to create a framework for assured payouts under the National Pension Scheme (NPS).
Petroleum Minister Hardeep Puri discusses LNG, LPG, and green hydrogen cooperation with British Columbia's Premier to enhance India-Canada energy partnership.
Rupee falls 4 paise to 90.21 against the dollar due to rising crude prices and geopolitical tensions.
Indian markets fell amid foreign fund outflows and profit-booking in blue chips, influenced by global tariff concerns and weak earnings.
Himachal CM Sukhu vows to address apple import duty concerns to protect local growers' livelihoods amid New Zealand trade changes.
India drops to third in Russian fossil fuel imports in December, as Reliance cuts crude purchases, totaling €2.3 billion.
Meta plans to cut around 10% of the employees in its Reality Labs division who work on products including the metaverse, the New York Times reported